Is neurobeachin ( NBEA ) a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma?
The NBEA gene at 13q13, and its expression are frequently disrupted in MM. Additional studies are warranted to evaluate the role of NBEA as a novel candidate tumor-suppressor gene.
Adjuvant therapy would not be indicated to patients with pT3aN0 PCA with negative LVI and PSA < or =10 ng/mL.